Skip to main content
. 2022 Jul 31;55(7):336–341. doi: 10.5483/BMBRep.2022.55.7.003

Fig. 4.

Fig. 4

Proangiogenic effects of DPSCs mediated by VEGF. Effects of the DPSCs CM on differentiation (A), proliferation (B), and signaling pathways (C, D) of HUVECs with or without bevacizumab, a VEGF neutralizing antibody, were analyzed and compared. *P < 0.05.